Comparative effectiveness and implementation research: Directions for Neurology

被引:13
作者
Vickrey, Barbara G. [1 ,2 ]
Hirtz, Deborah [3 ]
Waddy, Salina [3 ]
Cheng, Eric M. [1 ,2 ]
Johnston, S. Claiborne [4 ]
机构
[1] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA
[2] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[3] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
HEALTH-SERVICES RESEARCH; MYOCARDIAL-INFARCTION; ETHNIC DISPARITIES; CONTROLLED-TRIAL; STROKE; OUTCOMES; WARFARIN; EPILEPSY; THERAPY; ASPIRIN;
D O I
10.1002/ana.22672
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is an enormous unmet need for knowledge about how new insights from discovery and translational research can yield measurable, population-level improvements in health and reduction in mortality among those having or at risk for neurological disease. Once several, well-conducted randomized controlled trials establish the efficacy of a given therapy, implementation research can generate new knowledge about barriers to uptake of the therapy into widespread clinical care, and what strategies are effective in overcoming those barriers and in addressing health disparities. Comparative effectiveness research aims to elucidate the relative value (including clinical benefit, clinical harms, and/or costs) of alternative efficacious management approaches to a neurological disorder, generally through direct comparisons, and may include comparisons of methodologies for implementation. Congress has recently appropriated resources and established an institute to prioritize funding for such research. Neurologists and neuroscientists should understand the scope and objectives of comparative effectiveness and implementation research, their range of methodological approaches (formal literature syntheses, randomized trials, observational studies, modeling), and existing research resources (centers for literature synthesis, registries, practice networks) relevant to research for neurological conditions, to close the well-documented evidence-to-practice gap. Future directions include building this research resource capacity, producing scientists trained to conduct rigorous comparative effectiveness and implementation research, and embracing innovative strategies to set research priorities in these areas. Ann Neurol 2012;71:732742
引用
收藏
页码:732 / 742
页数:11
相关论文
共 59 条
[1]  
Agency for Healthcare Research and Quality, 2010, ELECT NEWSLETTE 1210
[2]  
Agency for Healthcare Research and Quality, EPC TOP NOM SEL
[3]  
[Anonymous], 2020, RES C DE LIST OFF PA
[4]  
[Anonymous], 2009, IN NAT PRIOR COMP EF, DOI DOI 10.17226/12648
[5]  
[Anonymous], UN TREATM CONFR RAC
[6]  
[Anonymous], 2010, AHRQ PUBLICATION
[7]  
[Anonymous], 10038 PAR
[8]   A COMPARISON OF RESULTS OF METAANALYSES OF RANDOMIZED CONTROL TRIALS AND RECOMMENDATIONS OF CLINICAL EXPERTS - TREATMENTS FOR MYOCARDIAL-INFARCTION [J].
ANTMAN, EM ;
LAU, J ;
KUPELNICK, B ;
MOSTELLER, F ;
CHALMERS, TC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (02) :240-248
[9]  
Berg AO, 2009, AM FAM PHYSICIAN, V80, P1218
[10]   Intensity of aphasia therapy, impact on recovery [J].
Bhogal, SK ;
Teasell, R ;
Speechley, M .
STROKE, 2003, 34 (04) :987-992